Reliant Investment Management LLC Purchases 44,722 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Reliant Investment Management LLC boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 834.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 50,080 shares of the biopharmaceutical company’s stock after purchasing an additional 44,722 shares during the period. Bristol-Myers Squibb comprises about 2.1% of Reliant Investment Management LLC’s investment portfolio, making the stock its 26th biggest position. Reliant Investment Management LLC’s holdings in Bristol-Myers Squibb were worth $2,945,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in BMY. Perennial Advisors LLC bought a new position in Bristol-Myers Squibb during the 1st quarter valued at about $27,000. CVA Family Office LLC acquired a new stake in Bristol-Myers Squibb in the 1st quarter valued at about $28,000. Laidlaw Wealth Management LLC increased its position in Bristol-Myers Squibb by 11,407.0% in the 2nd quarter. Laidlaw Wealth Management LLC now owns 1,900,156 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 1,883,643 shares in the last quarter. JCIC Asset Management Inc. increased its position in Bristol-Myers Squibb by 37.8% in the 2nd quarter. JCIC Asset Management Inc. now owns 620 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 170 shares in the last quarter. Finally, HBC Financial Services PLLC increased its position in Bristol-Myers Squibb by 166.7% in the 2nd quarter. HBC Financial Services PLLC now owns 800 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 500 shares in the last quarter. 72.61% of the stock is owned by hedge funds and other institutional investors.

NYSE BMY traded down $0.17 during trading on Tuesday, reaching $59.53. 8,257,868 shares of the stock traded hands, compared to its average volume of 14,360,183. The company has a quick ratio of 1.36, a current ratio of 1.47 and a debt-to-equity ratio of 0.85. Bristol-Myers Squibb Co has a fifty-two week low of $45.76 and a fifty-two week high of $68.34. The stock’s 50-day moving average price is $60.92 and its 200 day moving average price is $59.16. The firm has a market cap of $135.08 billion, a price-to-earnings ratio of -597.44, a price-to-earnings-growth ratio of 1.10 and a beta of 0.70.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.48 by $0.15. Bristol-Myers Squibb had a negative net margin of 1.61% and a positive return on equity of 28.47%. The firm had revenue of $10.13 billion for the quarter, compared to analyst estimates of $10.04 billion. During the same quarter in the previous year, the firm posted $1.18 earnings per share. The business’s revenue was up 61.5% on a year-over-year basis. Analysts anticipate that Bristol-Myers Squibb Co will post 6.24 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend is Thursday, October 1st. Bristol-Myers Squibb’s payout ratio is currently 38.38%.

Several equities research analysts have weighed in on BMY shares. Cantor Fitzgerald raised their price objective on shares of Bristol-Myers Squibb from $68.00 to $88.00 in a research report on Tuesday, June 2nd. Raymond James started coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, July 28th. They issued an “outperform” rating and a $75.00 price objective for the company. Cfra restated a “buy” rating and issued a $70.00 price objective on shares of Bristol-Myers Squibb in a research report on Sunday, July 26th. ValuEngine cut shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Monday, June 1st. Finally, Seaport Global Securities began coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, July 28th. They set an “outperform” rating and a $75.00 price target for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $70.08.

In other news, EVP Sandra Leung sold 141,420 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $63.24, for a total value of $8,943,400.80. Following the sale, the executive vice president now owns 432,744 shares of the company’s stock, valued at $27,366,730.56. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Joseph Eid sold 5,327 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $64.00, for a total transaction of $340,928.00. Following the completion of the sale, the senior vice president now directly owns 2,534 shares in the company, valued at approximately $162,176. The disclosure for this sale can be found here. In the last ninety days, insiders sold 186,587 shares of company stock worth $11,782,297. Insiders own 0.14% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: How the Dogs of the Dow Strategy Works

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.